The impact of blood lipids and statins on renal function and mortality in patients with diabetic nephropathy: A meta-analysis
By:
References
- M. K. Sagoo and L. Gnudi, Diabetic Nephropathy: An Overview, in Methods in Molecular Biology, Clifton 2020, p.p. 3–7; https://doi.org/10.1007/978-1-4939-9841-8_1
- C. Faselis, A. Katsimardou, K. Imprialos, P. Deligkaris, M. Kallistratos and K. Dimitriadis, Micro-vascular complications of type 2 diabetes mellitus, Curr. Vasc. Pharmacol. 18(2) (2020) 117–124; https://doi.org/10.2174/1570161117666190502103733
- R. Z. Alicic, M. T. Rooney and K. R. Tuttle, Diabetic kidney disease: Challenges, progress, and possibilities, Clin. J. Am. Soc. Nephrol. 12(12) (2017) 2032–2045; https://doi.org/10.2215/cjn.11491116
- S. M. Doshi and A. N. Friedman, Diagnosis and Management of Type 2 Diabetic Kidney Disease, Clin. J. Am. Soc. Nephrol. 12(8) (2017) 1366–1373; https://doi.org/10.2215/cjn.11111016
- K. Watanabe, E. Sato, E. Mishima, M. Miyazaki and T. Tanaka, What’s new in the molecular mechanisms of diabetic kidney disease: Recent advances, Int. J. Mol. Sci. 24(1) (2022) Article ID 570; https://doi.org/10.3390/ijms24010570
- C. E. Mogensen, C. K. Christensen and E. Vittinghus, The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy, Diabetes 32(Suppl 2) (1983) 64–78; https://doi.org/10.2337/diab.32.2.s64
- H. Ali, M. Abu-Farha, M. M. Hammad, S. Devarajan, Y. Bahbahani, I. Al-Khairi, P. Cherian, Z. Alsairafi, V. Vijayan, F. Al-Mulla, A. A. Attar and J. Abubaker, Potential role of N-cadherin in diagnosis and prognosis of diabetic nephropathy, Front. Endocrinol. 13 (2022) Article ID 882700 (8 pages); https://doi.org/10.3389/fendo.2022.882700
- M. Akhtar, N. M. Taha, A. Nauman, I. B. Mujeeb and A. Al-Nabet, Diabetic kidney disease: Past and present, Adv. Anat. Pathol. 27(2) (2020) 87–97; https://doi.org/10.1097/pap.0000000000000257
- C. Yang, H. Wang, X. Zhao, K. Matsushita, J. Coresh, L. Zhang and M. H. Zhao, CKD in China: Evolving spectrum and public health implications, Am. J. Kidney Dis. 76(2) (2020) 258–264; https://doi.org/10.1053/j.ajkd.2019.05.032
- S. Eid, K. M. Sas, S. F. Abcouwer, E. L. Feldman, T. W. Gardner, S. Pennathur and P. E. Fort, New insights into the mechanisms of diabetic complications: role of lipids and lipid metabolism, Diabetologia 62 (2019) 1539–1549; https://doi.org/10.1007/s00125-019-4959-1
- X. Zhang, Y. Wang, Z. Yang, X. Chen, J. Zhang, X. Wang, X. Jin, L. Wu, X. Xing, W. Yang and B. Zhang, Development and assessment of diabetic nephropathy prediction model using hub genes identified by weighted correlation network analysis, Aging 14(19) (2022) 8095–8109; https://doi.org/10.18632/aging.204340
- X. Li, J. Liao and Z. Guo, Detection value of FOXO1 gene methylation, blood glucose and lipids in patients with type 2 diabetic kidney disease, Medicine 101(49) (2022) Article ID e31663 (5 pages); https://doi.org/10.1097/md.0000000000031663
- N. D. Vaziri, Disorders of lipid metabolism in nephrotic syndrome: mechanisms and consequences, Kidney Int. 90(1) (2016) 41–52; https://doi.org/10.1016/j.kint.2016.02.026
- T. Toyama, M. Shimizu, K. Furuichi, S. Kaneko and T. Wada, Treatment and impact of dyslipidemia in diabetic nephropathy, Clin. Exp. Nephrol. 18 (2014) 201–205; https://doi.org/10.1007/s10157-013-0898-1
- B. A. Perkins, I. Bebu, I. H. de Boer, M. Molitch, W. Tamborlane, G. Lorenzi, W. Herman, N. H. White, R. Pop-Busui, A. D. Paterson, T. Orchard, C. Cowie and J. M. Lachin, Risk factors for kidney disease in type 1 diabetes, Diabetes Care 42(5) (2019) 883–890; https://doi.org/10.2337/dc18-2062
- S. Khadka, G. K. Yadav, P. Subedi, K. Amgain, A. Sharma and R. Joshi, Association of urinary albumin-to-creatinine ratio with lipid abnormalities and glycemic control in patients with type 2 diabetes mellitus, Ann. Med. Surgery 85(9) (2023) 4329–4333; https://doi.org/10.1097/ms9.0000000000001045
- S. O. Almeida and M. Budoff, Effect of statins on atherosclerotic plaque, Trends Cardiovasc. Med. 29(8) (2019) 451–455; https://doi.org/10.1016/j.tcm.2019.01.001
- L. Opazo-Ríos, S. Mas, G. Marín-Royo, S. Mezzano, C. Gómez-Guerrero, J. A. Moreno and J. Egido, Lipotoxicity and diabetic nephropathy: Novel mechanistic insights and therapeutic opportunities, Int. J. Mol. Sci. 21(7) (2020) Article ID 2632 (30 pages); https://doi.org/10.3390/ijms21072632
- S. Zhou, P. Zhao, Y. Li, T. Deng, L. Tian and H. Li, Renoprotective effect of atorvastatin on STZ-diabetic rats through attenuating kidney-associated dysmetabolism, Eur. J. Pharmacol. 740 (2014) 9–14; https://doi.org/10.1016/j.ejphar.2014.06.055
- J. Lv, C. Ren and Q. Hu, Effect of statins on the treatment of early diabetic nephropathy: a systematic review and meta-analysis of nine randomized controlled trials, Ann. Palliat. Med. 10(11) (2021) 11548–11557; https://doi.org/10.21037/apm-21-2673
- X. Shen, Z. Zhang, X. Zhang, J. Zhao, X. Zhou, Q. Xu, H. Shang, J. Dong and L. Liao, Efficacy of statins in patients with diabetic nephropathy: a meta-analysis of randomized controlled trials, Lipids Health Dis. 15 (2016) Article ID 179 (11 pages); https://doi.org/10.1186/s12944-016-0350-0
- D. de Zeeuw, D. A. Anzalone, V. A. Cain, M. D. Cressman, H. J. Heerspink, B. A. Molitoris, J. T. Monyak, H. H. Parving, G. Remuzzi, J. R. Sowers and D. G. Vidt, Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): A randomised clinical trial, Lancet Diabetes Endocrinol. 3(3) (2015) 181–190; https://doi.org/10.1016/s2213-8587(14)70246-3
- X. Qin, H. Dong, K. Fang and F. Lu, The effect of statins on renal outcomes in patients with diabetic kidney disease: A systematic review and meta-analysis, Diabetes/metabolism Res. Rev. 33 (2017) 10.1002/dmrr.2901
- K. Hanai, T. Babazono and Y. Uchigata, Effects of statins on the kidneys in patients with type 2 diabetes, Clin. Exp. Nephrol. 21 (2017) 633–642; https://doi.org/10.1007/s10157-016-1329-x
- M. J. Page, J. E. McKenzie, P. M. Bossuyt, I. Boutron, T. C. Hoffmann, C. D. Mulrow, L. Shamseer, J. M. Tetzlaff, E. A. Akl, S. E. Brennan, R. Chou, J. Glanville, J. M. Grimshaw, A. Hróbjartsson, M. M. Lalu, T. Li, E. W. Loder, E. Mayo-Wilson, S. McDonald, L. A. McGuinness, L. A. Stewart, J. Thomas, A. C. Tricco, V. A. Welch, P. Whiting and D. Moher, The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, BMJ (Clin. Res. Ed.) 372 (2021) Article ID n71; https://doi.org/10.1136/bmj.n71
- M. Oremus, C. Wolfson, A. Perrault, L. Demers, F. Momoli and Y. Moride, Interrater reliability of the modified Jadad quality scale for systematic reviews of Alzheimer’s disease drug trials, Dement. Geriatr. Cogn. Disord. 12(3) (2001) 232–236; https://doi.org/10.1159/000051263
- X. Xue, C. L. Lu, X. Y. Jin, X. H. Liu, M. Yang, X. Q. Wang, H. Cheng, J. Yuan, Q. Liu, R. X. Zheng, N. Robinson and J. P. Liu, Relationship between serum uric acid, all-cause mortality and cardiovascular mortality in peritoneal dialysis patients: systematic review and meta-analysis of cohort studies, BMJ Open 11 (2021) Article ID e052274 (13 pages); https://doi.org/10.1136/bmjopen-2021-052274
- F. Abbasalizadeh, P. Saleh, R. Dousti, R. Piri, M. Naghavi-Behzad and S. Abbasalizadeh, Effects of atorvastatin on proteinuria of type 2 diabetic nephropathy in patients with history of gestational diabetes mellitus: A clinical study, Niger. Med. J. 58(2) (2017) 63–67; https://doi.org/10.4103/0300-1652.219348
- M. Abe, N. Maruyama, K. Okada, S. Matsumoto, K. Matsumoto and M. Soma, Effects of lipid-lowering therapy with rosuvastatin on kidney function and oxidative stress in patients with diabetic nephropathy, J. Atheroscler. Thrombosis 18(11) (2011) 1018–1028; https://doi.org/10.5551/jat.9084
- G. B. Appel, J. Radhakrishnan, M. M. Avram, R. A. DeFronzo, F. Escobar-Jimenez, M. M. Campos, E. Burgess, D. A. Hille, T. Z. Dickson, S. Shahinfar and B. M. Brenner, Analysis of metabolic parameters as predictors of risk in the RENAAL study, Diabetes Care 26(5) (2003) 1402–1407; https://doi.org/10.2337/diacare.26.5.1402
- H. M. Colhoun, D. J. Betteridge, P. N. Durrington, G. A. Hitman, H. A. Neil, S. J. Livingstone, V. Charlton-Menys, D. A. DeMicco and J. H. Fuller, Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS), Am. J. Kidney Dis. 54(5) (2009) 810–819; https://doi.org/10.1053/j.ajkd.2009.03.022
- S. Fava, J. Azzopardi, S. Ellard and A. T. Hattersley, ACE gene polymorphism as a prognostic indicator in patients with type 2 diabetes and established renal disease, Diabetes care 24(12) (2001) 2115–2120; https://doi.org/10.2337/diacare.24.12.2115
- A. K. Götz, C. A. Böger, C. Hirschmann, G. Schmitz, G. A. Riegger and B. K. Krämer, Effect of HMGCoA-reductase inhibitors on survival in type 2 diabetes patients with end stage diabetic nephropathy, Eur. J. Med. Res. 10(4) (2005) 155–160.
- E. B. Jude, S. G. Anderson, J. K. Cruickshank, A. Srivatsa, N. Tentolouris, R. Chandrasekaran, R. Gokal and A. J. Boulton, Natural history and prognostic factors of diabetic nephropathy in type 2 diabetes, QJM 95(6) (2002) 371–377; https://doi.org/10.1093/qjmed/95.6.371
- W. Kaewput, C. Thongprayoon, A. Chewcharat, R. Rangsin, B. Satirapoj, C. Kaewput, P. Suwannahitatorn, T. Bathini, M. A. Mao, L. D. Cato, A. M. Harrison, P. Vaitla and W. Cheungpasitporn, Rate of kidney function decline and factors predicting progression of kidney disease in type 2 diabetes mellitus patients with reduced kidney function: A nationwide retrospective cohort study, Therap. Apheresis Dialysis 24(6) (2020) 677–687; https://doi.org/10.1111/1744-9987.13480
- W. März, B. Genser, C. Drechsler, V. Krane, T. B. Grammer, E. Ritz, T. Stojakovic, H. Scharnagl, K. Winkler, I. Holme, H. Holdaas and C. Wanner, Atorvastatin and low-density lipoprotein chole sterol in type 2 diabetes mellitus patients on hemodialysis, Clin. J. Soc. Nephrol. 6(6) (2011) 1316–1325; https://doi.org/10.2215/cjn.09121010
- F. R. McCausland, B. Claggett, E. A. Burdmann, K. U. Eckardt, R. Kewalramani, A. S. Levey, J. J. McMurray, P. Parfrey, G. Remuzzi, A. K. Singh, S. D. Solomon, R. D. Toto and M. A. Pfeffer, C-Reactive protein and risk of ESRD: Results from the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT), Am. J. Kidney Dis. 68(6) (2016) 873–881; https://doi.org/10.1053/j.ajkd.2016.07.022
- T. Nakamura, T. Sugaya, Y. Kawagoe, Y. Ueda, S. Osada and H. Koide, Effect of pitavastatin on uri-nary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy, Diabetes Care 28(11) (2005) 2728–2732; https://doi.org/10.2337/diacare.28.11.2728
- T. Nakamura, C. Ushiyama, K. Hirokawa, S. Osada, N. Shimada and H. Koide, Effect of cerivastatin on urinary albumin excretion and plasma endothelin-1 concentrations in type 2 diabetes patients with microalbuminuria and dyslipidemia, Am. J. Nephrol. 21(6) (2001) 449–454; https://doi.org/10.1159/000046648
- S. Nielsen, O. Schmitz, N. Møller, N. Pørksen, I. C. Klausen, K. G. Alberti and C. E. Mogensen, Renal function and insulin sensitivity during simvastatin treatment in type 2 (non-insulin-dependent) diabetic patients with microalbuminuria, Diabetologia 36 (1993) 1079–1086; https://doi.org/10.1007/bf02374502
- P. J. Saulnier, E. Gand, S. Ragot, G. Ducrocq, J. M. Halimi, C. Hulin-Delmotte, P. Llaty, D. Montaigne, V. Rigalleau, R. Roussel, G. Velho, P. Sosner, P. Zaoui and S. Hadjadj, Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE Cohort, Diabetes Care 37(5) (2014) 1425–1431; https://doi.org/10.2337/dc13-2580
- N. Seki, T. Matsumoto and M. Fukazawa, Relationship between the brain natriuretic peptide (BNP) level and prognosis of diabetic nephropathy with microalbuminuria: A 7-year follow-up study, Horm. Metab. Res. 50(5) (2018) 389–396; https://doi.org/10.1055/a-0603-3792
- R. Tang, Y. Liu, J. Chen, J. Deng, Y. Liu and Q. Xu, Association of a low ankle brachial index with progression to end-stage kidney disease in patients with advanced-stage diabetic kidney disease, Renal failure 45 (2023) 2160347; https://doi.org/10.1080/0886022x.2022.2160347
- G. Tonolo, M. Ciccarese, P. Brizzi, L. Puddu, G. Secchi, P. Calvia, M. M. Atzeni, M. G. Melis and M. Maioli, Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment, Diabetes Care 20(12) (1997) 1891–1895; https://doi.org/10.2337/diacare.20.12.1891
- M. I. Troya, J. Bonet, I. Salinas, F. Torres, J. Bonal, A. Sanmartí and R. Romero, Early intensive treatment improves outcomes in patients with glomerular hyperfiltration and type 2 diabetes, Med. Clin. 146(2) (2016) 55–60; https://doi.org/10.1016/j.medcli.2015.05.016
- B. J. von Scholten, H. Reinhard, T. W. Hansen, J. Oellgaard, H. H. Parving, P. K. Jacobsen and P. Rossing, Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria, Diabetologia 59 (2016) 1549–1557; https://doi.org/10.1007/s00125-016-3937-0
- B. J. von Scholten, H. Reinhard, T. W. Hansen, C. G. Schalkwijk, C. Stehouwer, H. H. Parving, P. K. Jacobsen and P. Rossing, Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria, J. Diab. Complicat. 30(2) (2016) 248–255; https://doi.org/10.1016/j.jdiacomp.2015.11.005
- Y. Wang, J. Zhang, J. Zhang, Y. Wu, R. Zhang, H. Ren, M. E. Cooper and F. Liu, Sex differences in biopsy-confirmed diabetic kidney disease, Front. Endocrinol. 12 (2021) Aericle ID 670674 (8 pages); https://doi.org/10.3389/fendo.2021.670674
- C. Wanner, V. Krane, W. März, M. Olschewski, J. F. Mann, G. Ruf and E. Ritz, Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis, N. Engl. J. Med. 353(3) (2005) 238–248; https://doi.org/10.1056/NEJMoa043545
- H. Yokoyama, O. Tomonaga, M. Hirayama, A. Ishii, M. Takeda, T. Babazono, U. Ujihara, C. Takahashi and Y. Omori, Predictors of the progression of diabetic nephropathy and the beneficial effect of angiotensin-converting enzyme inhibitors in NIDDM patients, Diabetologia 40 (1997) 405–411; https://doi.org/10.1007/s001250050694
- L. Zhao, F. Liu, L. Li, J. Zhang, T. Wang, R. Zhang, W. Zhang, X. Yang, X. Zeng, Y. Wang, Y. Wu, H. Yang, S. Wang, Y. Zhong, H. Xu, S. Wang, R. Guo, H. Ren, L. Yang, B. Su, J. Zhang, N. Tong, X. J. Zhou and M. E. Cooper, Solidified glomerulosclerosis, identified using single glomerular proteomics, predicts end-stage renal disease in Chinese patients with type 2 diabetes, Sci. Rep. 11 (2021) Article ID 4658 (14 pages); https://doi.org/10.1038/s41598-021-83856-z
- Y. Zou, L. Zhao, J. Zhang, Y. Wang, Y. Wu, H. Ren, T. Wang, R. Zhang, J. Wang, Y. Zhao, C. Qin, H. Xu, L. Li, Z. Chai, M. E. Cooper, N. Tong and F. Liu, Development and internal validation of machine learning algorithms for end-stage renal disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney disease, Renal Failure 44(1) (2022) 562–570; https://doi.org/10.1080/0886022x.2022.2056053
- I. N. Migdalis, I. M. Ioannidis, N. Papanas, A. E. Raptis, A. E. Sotiropoulos and G. D. Dimitriadis, On behalf of the Hellenic diabetic nephropathy study, hypertriglyceridemia and other risk factors of chronic kidney disease in type 2 diabetes: A hospital-based clinic population in Greece, J. Clin. Med. 11(11) (2022) Article ID 3224; https://doi.org/10.3390/jcm11113224
- R. Retnakaran, C. A. Cull, K. I. Thorne, A. I. Adler and R. R. Holman, Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74, Diabetes 55(6) (2006) 1832–1839; https://doi.org/10.2337/db05-1620
- M. Cusick, E. Y. Chew, B. Hoogwerf, E. Agrón, L. Wu, A. Lindley and F. L. Ferris, 3rd, Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report No. 26, Kidney Int. 66(3) (2004) 1173–1179; https://doi.org/10.1111/j.1523-1755.2004.00869.x
- H. Liu, X. Yao, L. Wang, J. Liu, X. Li, X. Fu, J. Liu, S. Dong and Y. Wang, The causal relationship between 5 serum lipid parameters and diabetic nephropathy: a Mendelian randomization study, Front. Endocrinol. 15 (2024) Article ID 1358358 (8 pages); https://doi.org/10.3389/fendo.2024.1358358
- I. H. de Boer, B. C. Astor, H. Kramer, W. Palmas, S. L. Seliger, M. G. Shlipak, D. S. Siscovick, M. Y. Tsai and B. Kestenbaum, Lipoprotein abnormalities associated with mild impairment of kidney function in the multi-ethnic study of atherosclerosis, Clin. J. Am. Soc. Nephrol. 3(1) (2008) 125–132; https://doi.org/10.2215/cjn.03390807
- M. A. Gall, P. Hougaard, K. Borch-Johnsen and H. H. Parving, Risk factors for development of incipient and overt diabetic nephropathy in patients with non-insulin dependent diabetes mellitus: prospective, observational study, BMJ 314 (1997) 783–788; https://doi.org/10.1136/bmj.314.7083.783
- Y. Han, S. Xiong, H. Zhao, S. Yang, M. Yang, X. Zhu, N. Jiang, X. Xiong, P. Gao, L. Wei, Y. Xiao and L. Sun, Lipophagy deficiency exacerbates ectopic lipid accumulation and tubular cells injury in diabetic nephropathy, Cell Death Dis. 12 (2021) Article ID 1031 (13 pages); https://doi.org/10.1038/s41419-021-04326-y
- S. P. Srivastava, S. Shi, D. Koya and K. Kanasaki, Lipid mediators in diabetic nephropathy, Fibrogen. Tissue Rep. 7 (2014) Article ID 12 (10 pages); https://doi.org/10.1186/1755-1536-7-12
- K. McGrath and R. Edi, Diabetic kidney disease: Diagnosis, treatment, and prevention, Am. Family Physician 99(12) (2019) 751–759.
- D. Nikolic, M. Banach, S. Nikfar, P. Salari, D. P. Mikhailidis, P. P. Toth, M. Abdollahi, K. K. Ray, M. J. Pencina, J. Malyszko, J. Rysz and M. Rizzo, A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?, Int. J. Cardiol. 168(6) (2013) 5437–5447; https://doi.org/10.1016/j.ijcard.2013.08.060
- R. Zhao, W. Wang, W. Zhang, J. Lu, Y. Liu, J. Guo, L. Yang, Z. Zhang, C. He, X. Gu and B. Wang, Effects of genetically proxied statins on diabetic nephropathy and retinopathy: A Mendelian randomization study, Sci. Rep. 14 (2024) Article ID 16885 (10 pages); https://doi.org/10.1038/s41598-024-67800-5
- J. Atthobari, A. H. Brantsma, R. T. Gansevoort, S. T. Visser, F. W. Asselbergs, W. H. van Gilst, P. E. de Jong and L. T. de Jong-van den Berg, The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study, Nephrol. Dialysis Transplantation 21(11) (2006) 3106–3114; https://doi.org/10.1093/ndt/gfl244
- J. Sorof, C. Berne, A. Siewert-Delle, L. Jørgensen and P. Sager, Effect of rosuvastatin or atorvastatin on urinary albumin excretion and renal function in type 2 diabetic patients, Diab. Res. Clin. Pract. 72(1) (2006) 81–87; https://doi.org/10.1016/j.diabres.2005.09.004
- C. W. Nemerovski, J. Lekura, M. Cefaretti, P. T. Mehta and C. L. Moore, Safety and efficacy of statins in patients with end-stage renal disease, Ann. Pharmacother. 47(10) (2013) 1321–1329; https://doi.org/10.1177/1060028013501997
- C. Baigent, M. J. Landray, C. Reith, J. Emberson, D. C. Wheeler, C. Tomson, C. Wanner, V. Krane, A. Cass, J. Craig, B. Neal, L. Jiang, L. S. Hooi, A. Levin, L. Agodoa, M. Gaziano, B. Kasiske, R. Walker, Z. A. Massy, B. Feldt-Rasmussen, U. Krairittichai, V. Ophascharoensuk, B. Fellström, H. Holdaas, V. Tesar, A. Wiecek, D. Grobbee, D. de Zeeuw, C. Grönhagen-Riska, T. Dasgupta, D. Lewis, W. Herrington, M. Mafham, W. Majoni, K. Wallendszus, R. Grimm, T. Pedersen, J. Tobert, J. Armitage, A. Baxter, C. Bray, Y. Chen, Z. Chen, M. Hill, C. Knott, S. Parish, D. Simpson, P. Sleight, A. Young and R. Collins, The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): A randomised placebo-controlled trial, Lancet 377(9784) (2011) 2181–2192; https://doi.org/10.1016/s0140-6736(11)60739-3
- S. Y. Lin, C. L. Lin, W. H. Hsu, C. C. Lin, C. T. Chang and C. H. Kao, Association of statin use and the risk of end-stage renal disease: A nationwide Asian population-based case-control study, Eur. J. Internal Med. 31 (2016) 68–72; https://doi.org/10.1016/j.ejim.2016.02.012
- M. Soohoo, H. Moradi, Y. Obi, C. M. Rhee, E. O. Gosmanova, M. Z. Molnar, M. L. Kashyap, D. L. Gillen, C. P. Kovesdy, K. Kalantar-Zadeh and E. Streja, Statin therapy before transition to end-stage renal disease with posttransition outcomes, J. Am. Heart Assoc. 8(6) (2019) Article ID e011869; https://doi.org/10.1161/jaha.118.011869
- N. A. Mason, G. R. Bailie, S. Satayathum, J. L. Bragg-Gresham, T. Akiba, T. Akizawa, C. Combe, H. C. Rayner, A. Saito, B. W. Gillespie and E. W. Young, HMG-coenzyme a reductase inhibitor use is associated with mortality reduction in hemodialysis patients, Am. J. Kidney Dis. 45(1) (2005) 119–126; https://doi.org/10.1053/j.ajkd.2004.09.025
- S. L. Seliger, N. S. Weiss, D. L. Gillen, B. Kestenbaum, A. Ball, D. J. Sherrard and C. O. Stehman-Breen, HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients, Kidney Int. 61(1) (2002) 297–304; https://doi.org/10.1046/j.1523-1755.2002.00109.x
- U. Baber, R. D. Toto and J. A. de Lemos, Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure, Am. Heart J. 153(4) (2007) 471–477; https://doi.org/10.1016/j.ahj.2006.10.042
- T. S. Huang, T. Wu, Y. D. Wu, X. H. Li, J. Tan, C. H. Shen, S. J. Xiong, Z. Q. Feng, S. F. Gao, H. Li and W. B. Cai, Long-term statins administration exacerbates diabetic nephropathy via ectopic fat deposition in diabetic mice, Nature Comm. 14 (2023) Article ID 390 (19 pages); https://doi.org/10.1038/s41467-023-35944-z
- Y. Zhang, Y. Qu, R. Cai, J. Gao, Q. Xu, L. Zhang, M. Kang, H. Jia, Q. Chen, Y. Liu, F. Ren and M. S. Zhou, Atorvastatin ameliorates diabetic nephropathy through inhibiting oxidative stress and ferroptosis signaling, Eur. J. Pharmacol. 976 (2024) Article ID 176699; https://doi.org/10.1016/j.ejphar.2024.176699
Language: English
Page range: 1 - 22
Accepted on: Nov 12, 2024
Published on: Apr 10, 2025
Published by: Croatian Pharmaceutical Society
In partnership with: Paradigm Publishing Services
Publication frequency: 4 issues per year
Keywords:
Related subjects:
© 2025 Dongqin Tian, Qian Chen, Lingli Zeng, Yan Hao, published by Croatian Pharmaceutical Society
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.